Publication | Closed Access
Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3
Anouk C. Vedder,
Frank Breunig,
Wilma E. Donker‐Koopman,
Kevin Mills,
Elisabeth Young,
Bryan Winchester,
Ineke J. M. ten Berge,
J.E.M. Groener,
Johannes M. F. G. Aerts,
Christoph Wanner,
Molecular Genetics and MetabolismFabry DiseaseImmunologyPathologyMedicineAntibody Formation